Preparation method and application of anti-breast cancer implantation stent based on paclitaxel / polylactic acid composite material
By mixing paclitaxel with polylactic acid powder and preparing porous scaffolds using hot melt extrusion and 3D printing technology, the side effects caused by solvents and the inflammatory risk of metal scaffolds in the prior art are solved, and the slow release of paclitaxel and effective breasts are achieved. Cancer inhibitory effect.
Patent Information
- Application Number
- CN202411099821.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-22
AI Technical Summary
In the prior art, the stents used for breast cancer treatment for paclitaxel have problems such as solvent-induced allergic reactions, systemic toxicity and inflammatory infection of metal stents, as well as toxic reactions of too low porosity of the drug membrane, myelosuppression and fluid retention.
By mixing paclitaxel with polylactic acid powder, making wires using hot melt extrusion technology, and then printing into a porous sheet-like scaffold with surfaces using 3D printing technology, the slow release of paclitaxel is achieved, avoiding the defects of solvent use and metal scaffolds.
This method effectively reduces the proliferation of breast cancer cells, has few toxic and side effects, and is suitable for use in breast cancer treatment. The stent can be directly implanted into the lesion site, significantly inhibiting the growth of breast tumors.
Smart Images

Figure CN118987376A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of drug material preparation, and in particular to a preparation method and application of an anti-breast cancer implant stent based on paclitaxel / polylactic acid composite material. Background Art
[0002] Breast cancer is the most common malignant tumor in women and is currently treated mainly through surgery, radiotherapy and chemotherapy. Paclitaxel is widely used as the main chemotherapy drug in the treatment of breast cancer. Paclitaxel (PTX) has poor water solubility and clinically requires the use of a mixture of polyoxyethylene castor oil and ethanol as a solvent. During medication, allergic reactions caused by the solvent and systemic toxicity caused by systemic medication may occur.
[0003] Polylactic acid (PLA) is a polymer material with good biocompatibility and biodegradability. It can be converted into carbon dioxide and water in the body. In addition, PLA has high strength and toughness, as well as good thermoforming properties. 3D printed paclitaxel-PLA stents can avoid the side effects produced during the medication process and effectively inhibit the development of breast cancer. Therefore, the paclitaxel-PLA stent is a new dosage form of paclitaxel with anti-breast cancer effects. The preparation of paclitaxel-PLA stents can achieve the slow release of paclitaxel and achieve long-term effective treatment with low side effects.
[0004] The Chinese Patent Database has published a paclitaxel-loaded ethylene-vinyl acetate esophageal stent and its preparation method, with publication number: CN105232182A, and publication date: January 13, 2016; this method uses bare metal as a carrier, and is covered with ethylene-vinyl acetate and paclitaxel drug film layers on both sides, the inner side of the ethylene-vinyl acetate backing layer is in close contact with the bare metal stent, and the outer side of the ethylene-vinyl acetate backing layer is bonded to the paclitaxel drug film layer. However, the porosity of the drug film is too low, and the metal stent has the risk of inflammation and infection. The Chinese Patent Database also published a method for preparing a docetaxel / polylactic acid anti-tumor implant stent, with publication number: CN112618479A, and publication date: April 9, 2021. This method disperses docetaxel in a polylactic acid stent to form a new dosage form of docetaxel, but the toxic reactions of docetaxel in terms of bone marrow suppression and fluid retention are relatively serious. A stent film of paclitaxel presentingextreme accumulation of paclitaxel in tumor tissue and excellent antitumorefficacy after implantation beneath the subcutaneous tumor xenograft in mice A method for preparing a polylactic acid stent film loaded with paclitaxel was proposed. The adhesive double-layer film of paclitaxel drug film and polylactic acid drug-free film was obtained by organic solvent evaporation. The preparation speed of the drug film was slow and it did not have mechanical strength. Paclitaxel / sirolimus combination coated drug-eluting stent: In vitro and in vivo drugrelease studies A method for preparing a paclitaxel / sirolimus combination coated poly (d, l-lactide-co-glycolide) / amorphous calcium phosphate stent by coating was proposed. However, it was supported by a metal stent, the stent could not be degraded, and the biocompatibility was poor. (AWoven Vascular Stent-Grafts with Surface Modification of SilkFibroin-Based Paclitaxel / Metformin Microspheres) proposed a preparation method for paclitaxel / metformin loaded silk fibroin vascular stents through emulsification precipitation technology and electrostatic bonding layer-by-layer coating method, but the emulsification precipitation preparation is complicated and the preparation cycle is long.(Effect of a paclitaxel-eluting metallic stent on rabbit esophagus) A paclitaxel-eluting metallic stent was obtained to inhibit the growth of esophageal wall tumors, but the metal stent is non-degradable and has poor biocompatibility, which may cause adverse reactions such as inflammation. Summary of the invention
[0005] The purpose of the present invention is to overcome the defects in the prior art and provide a preparation method and application of an anti-breast cancer implant stent based on paclitaxel / polylactic acid composite material. The preparation method is simple, the implant stent can be directly implanted into the lesion site, effectively reducing breast cancer cell proliferation, and having little toxic and side effects.
[0006] The object of the present invention is achieved by: a method for preparing an anti-breast cancer implant stent based on paclitaxel / polylactic acid composite material, comprising the following steps: Step 1: uniformly mix paclitaxel and polylactic acid powder, and extrude the mixed powder into wires by hot melt extrusion technology at 170-180° C., wherein the mass concentration of paclitaxel in the wires is 0.5%-1.5%; Step 2: The wire obtained in step 1 is printed by 3D printing technology at 205-220° C. to obtain a PTX / PLA scaffold.
[0007] Furthermore, the wire diameter in step 1 is 1.7 mm to 1.8 mm; a wire that is too thin has poor fluidity during printing, is easy to break, and is difficult to control printing accuracy; a wire that is too thick may clog the printer nozzle and feed system, affecting the smooth progress of printing.
[0008] Furthermore, the PTX / PLA scaffold in step 2 is in the shape of a disc with a porous surface, and the disc size is 10mm*10mm*1mm; the porous disc increases the specific surface area of the PTX / PLA scaffold, which helps to release the active substance PTX.
[0009] The invention also discloses a PTX / PLA scaffold obtained by the preparation method of the invention and applies the scaffold to inhibit breast tumors.
[0010] When the present invention is working, the mixture of paclitaxel and polylactic acid is first made into filaments through hot melt extrusion technology, and then the mixed filaments are printed into a circular mesh porous scaffold according to a set shape through 3D printing technology. Through this mesh porous scaffold, paclitaxel can be slowly released at the lesion, avoiding allergic reactions caused by the use of solvents, and can effectively reduce the proliferation of breast cancer cells. It has little toxic side effects and is suitable for use in the treatment of breast cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] Figure 1This is a physical picture of the paclitaxel / polylactic acid stent prepared in Example 1.
[0012] Figure 2 This is the UV characterization diagram of the in vitro release of the paclitaxel / polylactic acid stent prepared in Example 1.
[0013] Figure 3 This is a picture of the stent implantation surgery in Example 2.
[0014] Figure 4 This is a picture of the stent after implantation in Example 2.
[0015] Figure 5 The figure shows the weight change curves of mice in the blank group, 0.5% PTX / PLA scaffold, 1.5% PTX / PLA scaffold and injection group.
[0016] Figure 6 The graph shows the change curves of tumor volume in mice in the blank group, 0.5% PTX / PLA scaffold, 1.5% PTX / PLA scaffold and injection group.
[0017] Figure 7 These are pictures of mouse tumors in the blank group, 0.5% PTX / PLA scaffold, 1.5% PTX / PLA scaffold, and injection group.
[0018] Figure 8 This is a curve chart of the changes in mouse organ indexes in the blank group, 0.5% PTX / PLA scaffold, 1.5% PTX / PLA scaffold, and injection group.
[0019] Fig. 9 Photos of mouse spleen in the blank group, 0.5% PTX / PLA scaffold, 1.5% PTX / PLA scaffold, and injection group.
[0020] Fig.10 HE staining of mouse tissue sections. DETAILED DESCRIPTION
[0021] The paclitaxel powder used in the following embodiments was from Dalian Meilun Biotechnology Co., Ltd., and the polylactic acid was purchased from Merck, Germany. Example 1
[0022] A method for preparing an anti-breast cancer implant stent based on a paclitaxel / polylactic acid composite material comprises the following steps: Step 1: uniformly mix paclitaxel and polylactic acid powders, and extrude the mixed powders into wires by hot melt extrusion technology at 175°C. The mass concentration of paclitaxel in the wires is 0.5%, and the diameter of the obtained wires is 1.7 mm. Step 2: The wire obtained in step 1 is printed into a porous disc at 215° C. by 3D printing technology. The disc size is 10 mm*10 mm*1 mm, and a PTX / PLA implantable stent is obtained.
[0023] Figure 1 The actual image of the PTX / PLA scaffold prepared in Example 1. The PTX / PLA scaffold containing 0.5% mass concentration was placed in a PBS buffer containing 10% ethanol at 37°C and 100 r / min, and the absorbance of the solution was recorded every other day. The release behavior of paclitaxel was analyzed by ultraviolet spectroscopy. The ultraviolet analysis results show that (such as Figure 2 As shown in the in vitro release UV characterization diagram, paclitaxel was slowly released from the stent as time went on. In the first 11 days, paclitaxel was rapidly released from the stent. Later, with the slow degradation of PLA, the release rate of paclitaxel tended to be stable. Example 2
[0024] A method for preparing an anti-breast cancer implant stent based on a paclitaxel / polylactic acid composite material comprises the following steps: Step 1: Paclitaxel and polylactic acid powders are mixed evenly, and the mixed powders are extruded into wires by hot melt extrusion technology at 175°C. The mass concentration of paclitaxel in the wires is 1.5%, and the diameter of the obtained wires is 1.7 mm; Step 2: The wire obtained in step 1 is printed into a porous disc at 215° C. by 3D printing technology. The disc size is 10 mm*10 mm*1 mm, and a PTX / PLA implantable stent is obtained.
[0025] The prepared implant scaffolds were sterilized by ultraviolet radiation and then implanted into mice with breast cancer cells at a distance of 0.5 cm from the tumor for biological experiments. Figure 3 This is a picture of the stent implantation operation in Example 2. Figure 4 This is a picture of the mice after stent implantation in Example 2. The mice survived well after stent implantation and did not experience adverse reactions such as inflammation. Example 3
[0026] A method for preparing an anti-breast cancer implant stent based on a paclitaxel / polylactic acid composite material comprises the following steps: Step 1: uniformly mix paclitaxel and polylactic acid powders, and extrude the mixed powders into wires by hot melt extrusion technology at 170°C. The mass concentration of paclitaxel in the wires is 1.5%, and the diameter of the obtained wires is 1.7 mm. Step 2: The wire obtained in step 1 is printed into a porous disc at 215° C. by 3D printing technology. The disc size is 10 mm*10 mm*1 mm, and a PTX / PLA implantable stent is obtained. Example 4
[0027] A method for preparing an anti-breast cancer implant stent based on a paclitaxel / polylactic acid composite material comprises the following steps: Step 1: Paclitaxel and polylactic acid powders are mixed evenly, and the mixed powders are extruded into wires by hot melt extrusion technology at 180°C. The mass concentration of paclitaxel in the wires is 1.5%, and the diameter of the obtained wires is 1.7 mm; Step 2: The wire obtained in step 1 is printed into a porous disc at 215° C. by 3D printing technology. The disc size is 10 mm*10 mm*1 mm, and a PTX / PLA implantable stent is obtained. Example 5
[0028] A method for preparing an anti-breast cancer implant stent based on a paclitaxel / polylactic acid composite material comprises the following steps: Step 1: Paclitaxel and polylactic acid powders are mixed evenly, and the mixed powders are extruded into wires by hot melt extrusion technology at 175°C. The mass concentration of paclitaxel in the wires is 1.5%, and the diameter of the obtained wires is 1.7 mm; Step 2: The wire obtained in step 1 is printed into a porous disc at 205° C. by 3D printing technology. The disc size is 10 mm*10 mm*1 mm, and a PTX / PLA implantable stent is obtained. Example 6
[0029] A method for preparing an anti-breast cancer implant stent based on a paclitaxel / polylactic acid composite material comprises the following steps: Step 1: Paclitaxel and polylactic acid powders are mixed evenly, and the mixed powders are extruded into wires by hot melt extrusion technology at 175°C. The mass concentration of paclitaxel in the wires is 1.5%, and the diameter of the obtained wires is 1.7 mm; Step 2: The wire obtained in step 1 is printed into a porous disc at 210° C. by 3D printing technology. The disc size is 10 mm*10 mm*1 mm, and a PTX / PLA implantable stent is obtained. Example 7
[0030] A method for preparing an anti-breast cancer implant stent based on a paclitaxel / polylactic acid composite material comprises the following steps: Step 1: Paclitaxel and polylactic acid powders are mixed evenly, and the mixed powders are extruded into wires by hot melt extrusion technology at 175°C. The mass concentration of paclitaxel in the wires is 1.5%, and the diameter of the obtained wires is 1.7 mm; Step 2: The wire obtained in step 1 is printed into a porous disc at 220° C. by 3D printing technology. The disc size is 10 mm*10 mm*1 mm, and a PTX / PLA implantable stent is obtained.
[0031] When the printing temperature is higher than 220℃, the filament may degrade due to overheating. When it is lower than 205℃, the probability of filament printing failure increases. By controlling the printing temperature to 205~220℃, it can ensure that the PLA material melts smoothly and is extruded evenly. Example 8
[0032] A method for preparing an anti-breast cancer implant stent based on a paclitaxel / polylactic acid composite material comprises the following steps: Step 1: Paclitaxel and polylactic acid powders are mixed evenly, and the mixed powders are extruded into wires by hot melt extrusion technology at 175°C. The mass concentration of paclitaxel in the wires is 1.5%, and the diameter of the obtained wires is 1.8 mm; Step 2: The wire obtained in step 1 is printed into a porous disc at 215° C. by 3D printing technology. The disc size is 10 mm*10 mm*1 mm, and a PTX / PLA implantable stent is obtained.
[0033] Comparative Example 1: A group of mice with breast cancer cells were not treated with any drugs and served as a blank group. The mice grew normally, but the tumor volume continued to increase over time, and tumor cell invasion caused damage to the lungs and liver.
[0034] Comparative Example 2: A group of mice with breast cancer cells were injected with 8 mg / kg of paclitaxel by intraperitoneal injection. The tumor volume of the mice decreased after administration, but the systemic toxicity of paclitaxel caused the mice to lose weight, their kidneys to enlarge, and their spleens to shrink.
[0035] The 0.5% PTX / PLA scaffolds and 1.5% PTX / PLA scaffolds prepared in Examples 1 and 2 were implanted into mice seeded with breast cancer cells and compared with the mice in the blank group and the injection group. Figure 5 The figure is a curve chart of the weight changes of mice in the blank group, 0.5% PTX / PLA scaffold, 1.5% PTX / PLA scaffold and injection group. The mice in the blank group grew normally and their weight continued to increase. The weight of the mice in the scaffold implantation group showed an upward trend, and the increase was comparable to that in the blank group. The weight of the mice in the 1.5% PTX / PLA scaffold group dropped for a short period of time, which was due to surgical trauma and returned to normal later. The mice in the injection group were affected by drug toxicity and their weight showed a downward trend.
[0036] Figure 6The following is a graph showing the changes in tumor volume in mice in the blank group, 0.5% PTX / PLA scaffold, 1.5% PTX / PLA scaffold, and injection group. Due to the invasive characteristics of breast cancer, the four groups of mice showed consistent tumor growth patterns. Compared with the blank group, the tumor growth rates in the 0.5% PTX / PLA group, 1.5% PTX / PLA group, and injection group were reduced, which is related to the pharmacological effects of PTX. The 0.5% PTX / PLA scaffold was implanted in mice, and the mice grew normally and the increase in tumor volume was inhibited; the 1.5% PTX / PLA group had the greatest impact on tumor volume and effectively inhibited the increase in tumor volume.
[0037] Figure 7 The images of mouse tumors in the blank group, 0.5% PTX / PLA scaffold, 1.5% PTX / PLA scaffold, and injection group. The average tumor weight in the blank group was 0.9495 g, 0.6276 g in the 0.5% PTX / PLA scaffold group, 0.1476 g in the 1.5% PTX / PLA scaffold group, and 0.1636 g in the injection group. The tumor inhibition rates in the injection group, 0.5% PTX / PLA group, and 1.5% PTX / PLA group were 82.77%, 33.90%, and 84.46%, respectively. Organ coefficients and tissue sections were used to evaluate systemic toxicity and efficacy.
[0038] Figure 8 The curves of changes in organ indexes of mice in the blank group, 0.5% PTX / PLA scaffold, 1.5% PTX / PLA scaffold and injection group are shown in Figure 2. Fig. 9 The spleen of mice in the blank group, 0.5% PTX / PLA scaffold, 1.5% PTX / PLA scaffold and injection group. Paclitaxel accumulates in the spleen through blood circulation, inhibits spleen cell proliferation, and causes a significant decrease in spleen volume. The toxicity of paclitaxel causes slight kidney edema and kidney enlargement.
[0039] Fig.10HE staining of mouse tissue sections. No obvious pathological changes were found in the kidney and heart tissue sections of mice. The spleen tissue sections showed increased immune stress and increased number of immune cells in the injection group and 1.5% PTX / PLA scaffold group. Tumor cell metastasis, inflammatory cell infiltration, congestion, and alveolar wall thickening were observed in the lungs of the blank group mice, and congestion and alveolar wall thickening were observed in the 0.5% and 1.5% PTX / PLA scaffold groups. The liver sections showed that inflammatory cell infiltration was observed in the blank group, and the inflammatory cell infiltration in the injection group, 0.5% PTX / PLA scaffold group, and 1.5% PTX / PLA scaffold group was reduced, and the inflammatory cell infiltration in the 1.5% PTX / PLA scaffold group was the most significantly reduced. The tumor in the blank group developed normally, and some tumor cell death was observed in the 0.5% PTX / PLA scaffold group. A large number of tumor cell deaths occurred in the 1.5% PTX / PLA scaffold group and the injection group.
[0040] The present invention is not limited to the above-mentioned embodiments. On the basis of the technical solution disclosed in the present invention, technicians in this field can make some substitutions and deformations to some technical features therein according to the disclosed technical content without creative labor, and these substitutions and deformations are all within the protection scope of the present invention.
Claims
1. A method for preparing an anti-breast cancer implant stent based on paclitaxel / polylactic acid composite material, characterized in that: The steps include: Step 1: uniformly mix paclitaxel and polylactic acid powder, and extrude the mixed powder into wires by hot melt extrusion technology at 170-180° C., wherein the mass concentration of paclitaxel in the wires is 0.5%-1.5%; Step 2: The wire obtained in step 1 is printed by 3D printing technology at 205-220° C. to obtain a PTX / PLA scaffold.
2. The method for preparing an anti-breast cancer implant stent based on a paclitaxel / polylactic acid composite material according to claim 1, characterized in that: The wire diameter described in step 1 is 1.7 mm to 1.8 mm.
3. The method for preparing an anti-breast cancer implant stent based on a paclitaxel / polylactic acid composite material according to claim 1, characterized in that: The PTX / PLA scaffold in step 2 is in the shape of a disc with a porous surface, and the size of the disc is 10mm*10mm*1mm.
4. Use of the implant scaffold obtained by the preparation method according to any one of claims 1 to 3 in inhibiting breast tumors.
